(Q37611801)

21 August 2017

1 reference

title

Erlotinib in non-small-cell lung cancer: a review of the clinical and economic evidence (English)

1 reference

21 August 2017

1 reference

1 reference

Josh J Carlson

1

1 reference

21 August 2017

publication date

1 October 2009

1 reference

Expert Review of Pharmacoeconomics & Outcomes Research

21 August 2017

published in

1 reference

21 August 2017

volume

9

1 reference

21 August 2017

issue

5

1 reference

21 August 2017

page(s)

409-416

1 reference

Chemotherapy use, outcomes, and costs for older persons with advanced non-small-cell lung cancer: evidence from surveillance, epidemiology and end results-Medicare

21 August 2017

cites work

1 reference

Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials

21 January 2018

1 reference

Erlotinib in previously treated non-small-cell lung cancer

21 January 2018

1 reference

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

21 January 2018

1 reference

Erlotinib in non-small cell lung cancer treatment: current status and future development

21 January 2018

1 reference

Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients

21 January 2018

1 reference

Erlotinib in lung cancer - molecular and clinical predictors of outcome

21 January 2018

1 reference

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

21 January 2018

1 reference

Avastin-Tarceva combination fails in lung cancer

21 January 2018

1 reference

Do patients die from rashes from epidermal growth factor receptor inhibitors? A systematic review to help counsel patients about holding therapy

21 January 2018

1 reference

An interdisciplinary consensus on managing skin reactions associated with human epidermal growth factor receptor inhibitors.

21 January 2018

1 reference

HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum

21 January 2018

1 reference

Interstitial lung disease in patients with non-small-cell lung cancer treated with epidermal growth factor receptor inhibitors

21 January 2018

1 reference

A willingness-to-pay study of oral epidermal growth factor tyrosine kinase inhibitors in advanced non-small cell lung cancer

21 January 2018

1 reference

Epidermal growth factor tyrosine kinase inhibitors (EGFR TKIs) and economics

21 January 2018

1 reference

The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer

21 January 2018

1 reference

Comparative clinical and economic outcomes of treatments for refractory non-small cell lung cancer (NSCLC).

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERP.09.49

1 reference

21 August 2017

1 reference